IGC Pharma (IGC) EBIT Margin (2010 - 2025)
IGC Pharma (IGC) reported EBIT Margin of 1517.8% for Q3 2025, down 109062.0% year-over-year from N/an in Q3 2024, and down 161.33% quarter-over-quarter from 580.79% in Q2 2025.
IGC Pharma (IGC) EBIT Margin (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has 16 years of EBIT Margin data on file, last reported at 1517.8% in Q3 2025.
- EBIT Margin for Q3 2025 came in at 1517.8%, down 109062.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 731.92% (down 54122.0% YoY), and the FY2026 annual result was 775.39%, down 65777.0% from the prior year.
- EBIT Margin slipped to 1517.8% in Q3 2025 per IGC's latest filing, from 580.79% in the prior quarter.
- Over five years, EBIT Margin peaked at 5040.74% in Q1 2021 and troughed at 7764.29% in Q3 2021.
- A 5-year average of 436.5% and a median of 730.74% in 2024 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2021 and 2022: EBIT Margin tumbled 642349 bps in 2021, then jumped 653260 bps in 2022.
- A 5-year view of EBIT Margin shows it stood at 1679.58% in 2021, then surged by 59 bps to 686.14% in 2022, then slumped by 114 bps to 1469.61% in 2023, then soared by 50 bps to 730.74% in 2024, then plunged by 108 bps to 1517.8% in 2025.
- Business Quant data shows IGC's EBIT Margin at 1517.8% in Q3 2025, 580.79% in Q2 2025, and 428.18% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | IGC Pharma | 28.11 Mn | 27.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1,517.80% |
| Jun 30, 2025 | -580.79% |
| Mar 31, 2025 | -428.18% |
| Dec 31, 2024 | -730.74% |
| Sep 30, 2024 | -427.18% |
| Jun 30, 2024 | -880.88% |
| Mar 31, 2024 | 1,660.34% |
| Dec 31, 2023 | -1,469.61% |
| Sep 30, 2023 | -856.01% |
| Jun 30, 2023 | -385.41% |
| Mar 31, 2023 | 3,081.93% |
| Dec 31, 2022 | -686.14% |
| Sep 30, 2022 | -1,231.68% |
| Jun 30, 2022 | -1,321.70% |
| Mar 31, 2022 | 4,732.79% |
| Dec 31, 2021 | -1,679.58% |
| Sep 30, 2021 | -7,764.29% |
| Jun 30, 2021 | -2,849.35% |
| Mar 31, 2021 | 5,040.74% |
| Dec 31, 2020 | -2,153.70% |